Vir Biotechnology Valuation
Is VIR * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VIR * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VIR *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VIR *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VIR *?
Key metric: As VIR * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is VIR *'s PS Ratio? | |
|---|---|
| PS Ratio | 10.9x |
| Sales | US$118.80m |
| Market Cap | US$1.29b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VIR *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.4x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$24.6b |
AUPH Aurinia Pharmaceuticals | 5.8x | 17.3% | US$1.3b |
BCRX BioCryst Pharmaceuticals | 3.8x | 15.3% | US$1.6b |
NRIX Nurix Therapeutics | 26.7x | 28.9% | US$1.5b |
VIR * Vir Biotechnology | 10.9x | 23.7% | Mex$1.3b |
Price-To-Sales vs Peers: VIR * is good value based on its Price-To-Sales Ratio (10.9x) compared to the peer average (16.5x).
Price to Sales Ratio vs Industry
How does VIR *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
| 272 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 272 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: VIR * is expensive based on its Price-To-Sales Ratio (10.9x) compared to the Global Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is VIR *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 10.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate VIR *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
0%
1Y
6.3%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a